Uveitis Evaluation and Treatment 

  • Author: Robert H Janigian Jr, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: May 4, 2012
 

Approach to the Uveitis Workup

For many years, uveitis was considered a single disease entity; therefore, the approach to treatment varied very little. As knowledge of the disease process grew and the sophistication of immunologic and microbiologic testing increased, the fact that uveitis entails a multitude of diseases became clear. Although some diseases are local ocular immune phenomena, many of them are systemic diseases with ocular manifestations. Because the spectrum of disease pathogenesis ranges from autoimmunity to neoplasia to viruses, the practitioner of uveitis requires an understanding of internal medicine, infectious diseases, rheumatology, and immunology.

Patients with uveitis can present with some of the most challenging diagnostic dilemmas in all of ophthalmology. Because the treatment and prognosis of various uveitic entities varies greatly, accurate diagnosis is imperative. Many diseases, including Fuchs uveitis syndrome (formerly known as Fuchs heterochromic iridocyclitis), Behçet disease, toxoplasmosis, cytomegalovirus (CMV) retinitis, ocular histoplasmosis, and Vogt-Koyanagi-Harada (VKH) disease, are clinical diagnoses that require little, if any, laboratory analysis. Likewise, the patient presenting with an initial episode of acute nongranulomatous anterior uveitis and an unremarkable review of systems and physical examination does not require a laboratory evaluation.

Laboratory tests are rarely useful as screening tools for this disease. In determining which tests to order, using clues from the history and physical examination and knowledge of the pretest probability of the disease in question is helpful. This diagnostic process is important to avoid false-positive results and costly and unnecessary testing. Consequently, no standard laboratory evaluation exists for the patient with uveitis, except in screening for syphilis and possibly sarcoidosis, both of which can present in a myriad of ways. The key to the targeted and efficient patient evaluation is a thorough history, physical examination, and review of systems. With this information, the practitioner can generate a differential diagnosis and a subsequent strategy for laboratory evaluation.

For excellent patient education resources, visit eMedicine's Eye and Vision Center. Also, see eMedicine's patient education articles Iritis and Anatomy of the Eye.

The lists below include some of the most common systemic findings in patients with uveitis.

Head/CNS

Ear/Nose/Throat

  • Bilateral ear pinna inflammation - Relapsing polychondritis
  • Saddle nose deformity - Syphilis, Wegener granulomatosis, relapsing polychondritis
  • Oral ulcers - Behçet disease, SLE, herpes simplex, Reiter syndrome, ulcerative colitis
  • Sinusitis - Sarcoidosis, Wegener granulomatosis
  • Salivary/lacrimal gland swelling - Sarcoidosis, lymphoma
  • Lymphadenopathy - Lymphoma, HIV, toxoplasmosis

Gastrointestinal

Pulmonary

  • Cough, shortness of breath - Tuberculosis, sarcoidosis, Pneumocystis carinii, malignancy, Wegener granulomatosis
  • Nodules, hilar adenopathy, infiltrates - Ocular histoplasmosis, sarcoidosis (hilar adenopathy), malignancy, tuberculosis, P carinii pneumonia

Genitourinary

  • Genital ulcers - Behçet disease, Reiter syndrome, syphilis
  • Hematuria - Wegener granulomatosis, PAN, SLE
  • Circinate balanitis -Ankylosing spondylitis, Reiter syndrome
  • Urethral discharge - Reiter syndrome, syphilis
  • Nephritis - PAN, Wegener granulomatosis, tubulointerstitial nephritis and uveitis (TINU)
  • Epididymitis - PAN, Behçet disease, Reiter syndrome

Dermatologic

  • Alopecia - VKH disease, syphilis
  • Vitiligo, poliosis - VKH disease
  • Nodules - Sarcoidosis, SLE, leprosy, Crohn disease, ulcerative colitis
  • Rash - Syphilis, Lyme disease, Reiter syndrome, leprosy, sarcoidosis, herpes zoster, Behçet disease, psoriasis, SLE, Kawasaki disease
  • Keratoderma blennorrhagicum - Reiter syndrome, ankylosing spondylitis
  • Erythema nodosum - Behçet disease, sarcoidosis, APMPPE

Musculoskeletal

  • Arthralgias/arthritis - Behçet disease, sarcoidosis, SLE, juvenile idiopathic arthritis (JIA), Lyme disease, syphilis, psoriatic arthritis, Reiter syndrome, ulcerative colitis
  • Sacroiliitis - Ankylosing spondylitis, Reiter syndrome, inflammatory bowel disease

Constitutional

  • Fever - Reiter syndrome, Behçet disease, PAN, inflammatory bowel disease, HIV, tuberculosis, coccidioidomycosis, Whipple disease
  • Night sweats - Malignancy, tuberculosis, sarcoidosis, coccidioidomycosis
  • Flulike symptoms - APMPPE, multiple evanescent white dot syndrome (MEWDS)

Opremcak advocates a differential-based diagnostic system that primarily uses 3 clinical features, as follows: (1) location of the inflammation in the eye (corneoscleral, anterior, intermediate, posterior, or diffuse uveitis), (2) type of inflammation (granulomatous vs nongranulomatous), and (3) associated systemic symptoms from the review of systems.[1]

Smith and Nozik recommend a strategy called "name meshing."[2] The naming process involves extracting relevant clinical and historical information and creating a case profile (eg, acute unilateral nongranulomatous anterior uveitis in a 35-year-old white male with stiffness in the lower back). This information is meshed with clinical characteristics of known ocular inflammatory diseases. Using this information, the practitioner can generate a list of differential diagnoses and then order laboratory tests based on the likelihood that one of those diseases is present.

Although these systems work well, they are by no means foolproof. As the disease becomes chronic, the inflammation may change from nongranulomatous to granulomatous, the pattern of ocular involvement may change, and systemic features that were not initially present may become apparent. Because of the dynamic nature of uveitis, updating the review of systems and categorizing the ocular inflammation accordingly are important. Laboratory tests are no substitute for a systematic approach and careful observation in treating patients with uveitis.

Next

Choosing the Correct Diagnostic Test

Ordering a standard series of tests in every patient with uveitis is rarely useful, can be costly, and can often confuse the diagnostic process. Rosenbaum and Wernick emphasize the futility of indiscriminate testing.[3] The value of the test varies with the probability of the suspected disease (pretest probability). The test is most helpful in raising diagnostic probability to rule in levels when the history and physical examination findings create a pretest probability of 40-60%. Bayes theorem can be used to assess the use of positive results by evaluating the sensitivity and specificity of a diagnostic test combined with the pretest probability of disease to calculate the posttest probability of disease.

Responsible clinical physicians decide which diagnostic tests to order for patients based on the best possible evidence. Sackett and colleagues coined the term evidence-based medicine, which is "the conscientious, explicit and judicious use of the current best evidence in making decisions about the care of individuals."[4] Evidence-based medicine is a lifelong learning process, incorporating sound clinical skills with a proficiency for a critical appraisal of the medical literature. The following section is based on the excellent work by Sackett and colleagues; the reader is encouraged to consult the References section.[4]

Previous
Next

Evidence-based Medicine Approach to the Diagnosis of Uveitis

When a patient presents with intraocular inflammation, the diagnostic workup begins with the signs and symptoms. Each facet of the history and physical examination serves to either increase or decrease the probability of a target disorder being present. Unequivocally, the power of the clinical examination in establishing a diagnosis is far greater than the laboratory evaluation. Sandler discovered that after the history, a correct diagnosis was established in 56% of patients in a general medical clinic; it increased to 73% after the physical examination.[5] Routine laboratory evaluation helped to establish a diagnosis in only 5% of patients; not surprisingly, it also added substantial cost.

One strategy used by nearly all clinicians is the formulation of a list of potential diagnoses from a brief interaction with the patient, followed by a focused history and physical examination, and then an appropriate diagnostic evaluation that shortens the list of diagnostic possibilities. This strategy is termed the hypothetico-deductive approach by Sackett and colleagues.[4] In evaluating patients with uveitis, revisiting certain aspects of the history is common once particular facets of the examination become apparent. For example, after an initial interaction with a 34-year-old black woman with symptoms of redness, pain, and photophobia, the clinician discovers that she has mutton-fat keratic precipitates and iris nodules. Further questioning is directed toward the various entities that cause granulomatous inflammation, with the appropriate diagnostic tests ordered accordingly.

To understand the value of a particular diagnostic test, the concepts of pretest and posttest probability, sensitivity, specificity, and likelihood ratios (LRs) need to be introduced. Pretest probability, defined as the odds that a given disease exists in a specific patient with a particular constellation of signs and symptoms, greatly influences which diagnostic tests are ordered. Very few published pretest probability values exist for the various uveitic entities. Consequently, they usually are derived from the practitioner's clinical experience and intuition. Alternatively, colleagues can be consulted about their experiences, thereby generating a pretest probability by consensus.

A diagnostic test is only useful if it can confidently rule in or rule out disease. In other words, a reliable test is one that is positive in nearly all patients with the disease, giving the clinician confidence that the individual is disease free when the test result is negative (for that disease).

Some commonly used parameters for determining whether the evidence for a diagnostic test is important include the sensitivity and specificity of the test and the newer, more powerful concept of LRs. Sensitivity is the proportion of patients with the target disorder who have a positive test result (true positives), whereas specificity represents the proportion of patients without the target disorder who have a negative test result (true negatives). By using Bayes theorem, the posttest probability of disease (ie, likelihood that a disease is present after a test result is known) can be calculated, given the sensitivity and specificity of the diagnostic test and the pretest probability of the disease.

Knowing the posttest probability provides the clinician with objective evidence about a diagnostic conclusion or determines whether the clinician pursues further laboratory evaluation. Calculating the posttest probability from Bayes theorem is cumbersome and not always practical. Fortunately, an easier method using a nomogram, which interprets a diagnostic test result by using a newer concept (ie, LRs), is available. This attribute of a particular test indicates the probability that a given test result would be expected in a patient with the target disorder, compared to the probability that the same result would be present in a patient without the target disorder. Any valid article on diagnostic testing should provide information regarding the sensitivity and specificity of the test, and, if that is all that is given, then the LR can be calculated easily.

The LR for a positive test result is LR+ = sensitivity/1-specificity; the LR for a negative test result is LR- = 1-sensitivity/specificity. For example, a patient presents with retinal vasculitis and other signs and symptoms suggestive of Wegener granulomatosis. Literature is searched, and an article about the use of antineutrophil cytoplasmic antibodies (C-ANCA) with a cytoplasmic staining pattern in testing for Wegener granulomatosis is found. According to the article, 90% of patients with biopsy-proven disease had a positive C-ANCA (sensitivity), and 10% of patients had a positive test but other causes of systemic vasculitis (false positives or 1-specificity). Therefore, in this example, the LR+ is .9/.1 or 9. In other words, the positive C-ANCA in this patient is 9 times more likely to be observed in an individual with Wegener granulomatosis than without the disease.

By consulting the Fagan nomogram (conveniently located in the pocket guide Evidence-Based Medicine: How to Practice and Teach EBM by Sackett et al), the posttest probability of disease can be calculated.[4] For example, if a patient has a 50% chance of being diagnosed with the disease before the test, the LR of 9 translates into a posttest probability of 92%, suggesting that the C-ANCA was a very useful test.

More and more investigators are realizing the value of the LR as a measure of diagnostic accuracy and incorporating it in their reports. In addition to calculating the posttest probability, the LR has other advantages over the sensitivity and specificity; it is less likely to vary with the prevalence of the target disease, and it can be calculated for several levels of the diagnostic test, symptom, or sign (ie, very positive to weakly positive).

Ultimately, the usefulness of a diagnostic test is determined by whether it helps doctors in caring for their patients (ie, test results changing the management of patients with uveitis, patients benefiting as a result of the test). In the above example, the diagnosis of Wegener granulomatosis was crucial because treatment with cyclophosphamide favorably impacts the mortality rate and ocular complications. This section briefly introduced some concepts that are important to the diagnostic approach, particularly in diagnosing uveitis. The authors believe that implementing the principles of evidence-based medicine in the daily practice of medicine makes better clinicians and, more importantly, better doctors for patients.

Previous
Next

Diagnostic Approach to Specific Uveitic Entities

In an effort to better organize the classification and grading of various uveitic entities, the Standardization of Uveitis Nomenclature (SUN) Working Group published a consensus report in 2005.[6] This report provides clarification of the anatomical classification of uveitis. The reader is referred to this document as the prevailing methodology for the classification, descriptors, and terminology in the care of patients with uveitis.

Anterior uveitis

Patients with anterior uveitis present with a wide range of symptoms. These symptoms vary from a mild blurring of the vision with an otherwise normal-looking eye (ie, juvenile idiopathic arthritis [JIA]) to severe pain, photophobia, and loss of vision associated with intense injection and hypopyon. Factors other than ocular signs and symptoms can help in diagnosing anterior uveitis. The onset, duration, and severity of any symptom, as well as unilaterality or bilaterality of the disease, should be known. The patient's age, racial background, and ocular history should be taken into consideration. A detailed history and review of systems are of immeasurable value in the diagnostic approach to patients with uveitis.

An important element of any classification system for uveitis is defining what part of the eye is involved. The presence of white cells confined solely to the anterior chamber is called iritis. When the cellular activity involves the retrolental vitreous, the inflammatory process is believed to include the ciliary body and iris and is known as iridocyclitis. Corneal or scleral involvement plus anterior chamber inflammation is called keratouveitis or sclerouveitis, respectively.

Multiple etiologies are noted for anterior uveitis. Most types of anterior uveitis are sterile inflammatory reactions, as opposed to many of the posterior uveitic syndromes that are caused by infections. The percentage of idiopathic anterior uveitis ranges from approximately 38% to more than 70%; this is by far the most common cause of anterior uveitis.[7, 8] The next most common etiology is the sudden-onset human leukocyte antigen (HLA)-B27–positive or HLA-B27–associated disease.

McCannel reports that both community-based patients and university-based patients have similar incidence rates (about 17%).[9] After that, differences are observed in the probability of the various etiologies, depending on the clinical setting. For community-based patients, trauma is the third most common cause of anterior uveitis (5.7%); trauma was not observed in the university setting. Although herpes simplex virus is uncommon in community-based patients (1.9%), it was the third most likely diagnosis in the university setting (12.4%). Varicella-zoster infection occasionally was observed in both settings (5-6%). A large population-based study in Taiwan found that patients diagnosed with herpes zoster or herpes zoster ophthalmicus had a relative risk of anterior uveitis 1.67 and 13.06 times, respectively, greater than the comparison cohort during the first year after diagnosis.[10]

Pain, redness, and photophobia comprise the classic presentation of acute anterior uveitis. The pain usually is described as a dull ache in and around the eye, but anterior uveitis can cause little or no discomfort. Vision can be normal or slightly decreased. Often, the eye is extremely sensitive to light (photophobia). The patient may notice redness in one or both eyes or no change at all in the look of the eye.

The conjunctiva classically shows perilimbal injection (known as ciliary flush). The cornea may have keratic precipitates, which are clusters of WBCs collected on the endothelium. The type of keratic precipitate can provide a clue to the classification of anterior uveitis. Mutton-fat keratic precipitates are characteristic of granulomatous uveitis. Diffuse stellate keratic precipitates classically are seen in Fuchs uveitis syndrome. Interstitial keratitis commonly is seen in patients with syphilis and herpetic disease.

By definition, the anterior chamber has variable amounts of white cells floating in the aqueous. Often, protein also is visible in the anterior chamber as flare. If enough white cells deposit on the bottom of the chamber, a hypopyon results. This finding is suggestive of HLA-B27 disease, Behçet disease, or endophthalmitis.

The intraocular pressure (IOP) is often low in acute cases of anterior uveitis (with the exception of herpetic uveitis) but may be elevated in chronic cases.

The iris can provide additional information about the possible etiology or chronicity of the disease. Long-standing inflammation can cause posterior synechiae. Inflammatory nodules on the iris suggest granulomatous uveitis. Heterochromia is the classic finding in Fuchs uveitis syndrome. Atrophy of the iris may point to herpes zoster as the infection responsible for the inflammation.

The lens may show signs of cataractous change, which may suggest repeated bouts of iritis, or inflammatory precipitates may be present on the anterior lens capsule.

The anterior vitreous may have some cells that have "spilled over" from the anterior chamber. Some HLA-B27 diseases have varying amounts of vitritis and posterior pole involvement.

Papillitis or disc edema may be seen in Vogt-Koyanagi-Harada (VKH) disease, sarcoidosis, tuberculosis, Lyme disease, multiple sclerosis, toxoplasmosis, and toxocariasis.

In terms of testing, HLA-B27 is a genotype located on the short arm of chromosome 6 and is sometimes associated with specific rheumatologic diseases. HLA-B27 is present in 1.4-8% of the general population; however, it is present in as many as 50-60% of patients with acute iritis. The HLA-B27 test should be considered in patients with recurrent anterior nongranulomatous uveitis. These so-called seronegative spondyloarthropathies are associated strongly with both acute anterior uveitis and a positive HLA-B27 test. By definition, patients with these disorders do not have a positive rheumatoid factor. Some examples include ankylosing spondylitis, Reiter syndrome, inflammatory bowel disease, psoriatic arthritis, and postinfectious arthritis.

A thorough review of systems frequently directs the clinician toward the correct diagnosis. The possibility always exists of other systemic inflammatory disorders, some of which can be cured or at least managed. Syphilis, tuberculosis, Lyme disease, and herpes viruses are infectious diseases that can present as an anterior uveitis.

History is important in determining risk factors, but laboratory evidence of the disease is necessary so proper antibiotic therapy can be initiated quickly. Sarcoidosis is a systemic disease that classically manifests as an anterior granulomatous uveitis but can present as any type of uveitis. Judicious use of laboratory tests should help to better define the etiology of any anterior uveitis.

Table 1 is provided as a guide to the various clinical scenarios that may be confronted by the clinician. Beginning with knowledge of the type of inflammation, eliciting some associated factors should lead to a possible disease. Then, confirmatory laboratory tests can be used to establish a diagnosis. In general, a workup is required if the anterior uveitis is bilateral, severe, recurrent, or granulomatous or if the posterior segment is involved. Minimal laboratory testing should include CBC count, urinalysis, ACE, Venereal Disease Research Laboratory (VDRL) test, and fluorescent treponemal antibody absorption (FTA-ABS) test. Chest radiography should also be performed.

Table 1. Various Clinical Scenarios Encountered by Practitioner of Uveitis (Open Table in a new window)

Type of InflammationAssociated FactorsSuspected DiseaseLaboratory Tests
Acute/sudden onset, severe with or without fibrin membrane or hypopyonArthritis, back pain, GI/genitourinary symptomsSeronegative spondyloarthropathiesHLA-B27, sacroiliac films
Aphthous ulcersBehçet diseaseHLA-B5, HLA-B51
Postsurgical, posttraumaticInfectious endophthalmitisVitreous tap, vitrectomy
Medication inducedRifabutinNone
NoneIdiopathicPossibly HLA-B27
Moderate severity of pain and rednessShortness of breath, African descent, subcutaneous nodulesSarcoidosisSerum ACE, lysozyme, chest radiograph or chest CT scan, gallium scan, biopsy
PosttraumaticTraumatic iritis...
Increased IOP, sectorial iris atrophy, corneal dendriteHerpetic iritis...
Poor response to steroid, manifestations of 2° or 3° syphilis, HIVSyphilisRapid plasma reagent (RPR) or VDRL, FTA-ABS
Postcataract extraction, white plaque on posterior capsuleEndophthalmitis, intraocular lens (IOL)- related iritisVitrectomy and/or culture, consider anaerobic and fungal cultures
Medication inducedEtidronate (Didronel), metipranolol (OptiPranolol), latanoprost (Xalatan)
History of HIV, alcohol abuse, exposure to infected individuals, residence in endemic regionsTuberculosisPurified protein derivative (PPD), chest radiograph, referral to infectious disease specialist
NoneIdiopathic...
Chronic, minimal signs of redness or painChild, especially with arthritisJIA-related iridocyclitisAntinuclear antibody (ANA), erythrocyte sedimentation rate (ESR)
Heterochromia, diffuse stellate keratic precipitate, unilateralFuchs uveitis syndromeNone
PostsurgicalLow-grade endophthalmitis, IOLVitrectomy, capsulectomy with culture
NoneIdiopathicLyme titers (possibly)

Intermediate uveitis

Intermediate uveitis is an anatomical term suggested by the SUN Working Group. Intermediate uveitis is defined as intraocular inflammation that predominantly involves the peripheral retina, pars plana, and vitreous. Other terms used in the literature include chronic cyclitis, peripheral uveitis, and pars planitis. The term pars planitis is reserved to describe a subgroup of patients with idiopathic intermediate uveitis with snowbanking and/or snowball formation.

Intermediate uveitis accounts for approximately 8-15% of patients with uveitis in tertiary referral centers in the United States. Because characterization of this disease (and terminology associated with it) has been ambiguous, the conclusions of some older epidemiologic studies have been called into question. However, the report by Rodriguez et al used IUSG criteria and found that 162 of 1237 patients (13%) had intermediate uveitis, essentially confirming other studies.[7]

Patients typically present with painless blurred vision and floaters. Photophobia and redness are unusual.

Ocular findings include mild-to-moderate anterior segment inflammation, although anterior cellular activity may be more pronounced in children and in patients with multiple sclerosis. Presence of anterior vitreous cells is the sin qua non of this disorder, and, occasionally, the vitritis is severe enough to cause profound loss of vision. White clumps of inflammatory cells (called snowballs) tend to accumulate at the vitreous base where perivascular exudation and neovascularization may be present. The presence of a whitish yellow exudative material on the peripheral retina and the pars plana (called snowbanking) is commonly seen. The presence of this material facilitates the diagnosis but is not required to establish a diagnosis of intermediate uveitis. This finding is more consistent in patients with idiopathic intermediate uveitis and in children.

Because intermediate uveitis has been described in association with several systemic disorders, the initial diagnostic evaluation should exclude masquerade syndromes and infectious diseases in which immunosuppression may be ineffective or contraindicated. The diagnostic approach to intermediate uveitis should focus on the history and clinical examination. As stated by Henderly et al and also by Rodriguez et al, approximately two thirds of patients have idiopathic intermediate uveitis (pars planitis).[11, 7] Of the 162 patients with intermediate uveitis described by Rodriguez et al, 69% of them were idiopathic, sarcoidosis was diagnosed in 22% of them, multiple sclerosis was diagnosed in 8% of patients, and Lyme disease was diagnosed in only 1 patient.[7] Other entities have been reported to cause or to be confused with intermediate uveitis (see Table 2).

The authors' efforts focus on excluding sarcoidosis and multiple sclerosis with a thorough review of systems. Generally, the authors order an ACE level and a chest radiography for all patients to rule out subclinical sarcoidosis. The presence of neurologic symptoms or a history of optic neuritis may necessitate an MRI of the brain with subsequent neurologic consultation to rule out multiple sclerosis.

Patients from endemic areas for Lyme disease with a history of a rash typical of erythema migrans, chronic arthritis, or cranial nerve palsies undergo testing for antibodies to Borrelia burgdorferi. The authors seek consultation with a gastroenterologist for those patients with symptoms suggestive of inflammatory bowel disease or Whipple disease (if the diagnosis has not already been established). Older patients presenting with vitreous cells may be indicative of intraocular large cell lymphoma. Diagnostic vitrectomy, cytological evaluation of cerebrospinal fluid (CSF), and neuroimaging may be necessary.

Table 2. Other Entities Reported to Cause or Confused With Intermediate Uveitis (Open Table in a new window)

Clinical EntityDiagnostic Tests
Idiopathic (pars planitis)None
SarcoidosisACE, chest radiography, gallium scan, biopsy (possibly)
Multiple sclerosisMRI and neurologic consultation if history of neurologic symptoms or optic neuritis, HLA-DR2
Lyme diseaseLyme serology (immunoglobulin [Ig]G/IgM Western immunoblot testing) if from endemic area and/or presence of systemic signs
SyphilisVDRL, FTA-ABS
Inflammatory bowel diseaseGI consultation
Whipple diseaseGI consultation
LymphomaVitreous cytology with immunophenotyping, lumbar puncture for cytology, neuroimaging

Retinal vasculitis

Conditions causing retinal vasculitis are a heterogeneous group of disorders that include some of the most devastating medical diseases encountered by the ophthalmologist. The term vasculitis implies primary retinal vascular inflammation (ie, immune complex deposition due to type III hypersensitivity), as seen in Behçet disease, but vasculitis is commonly a sign of intraocular inflammation from other causes with secondary vascular involvement (eg, toxoplasmosis).

Some noninflammatory retinal vascular diseases can be associated with perivascular exudation, such as diabetic retinopathy, radiation retinopathy, sickle cell retinopathy, venous occlusive disease, and Coat disease. The differential diagnosis of retinal vasculitis can be subdivided broadly into those diseases that have systemic involvement and those diseases that are confined to the eye, as outlined below.

  • Systemic diseases associated with retinal vasculitis
    • Behçet disease
    • Syphilis
    • Systemic lupus erythematosus (SLE)
    • Tuberculosis
    • Sarcoidosis
    • Wegener granulomatosis
    • Toxoplasmosis
    • Cytomegalovirus (CMV)
    • Polyarteritis nodosa (PAN)
    • Candidiasis
    • Multiple sclerosis
    • Herpes zoster/herpes simplex
    • Giant cell arteritis
    • Lyme disease
    • Crohn disease
    • Rickettsia
    • Whipple disease
    • Large cell lymphoma
    • Polymyositis/dermatomyositis
  • Ocular diseases associated with retinal vasculitis
    • Eales disease
    • Frosted branch angiitis
    • Acute retinal necrosis
    • Retinal arteritis and aneurysms
    • Birdshot choroiditis
    • Toxoplasmosis
    • Pars planitis

Common presenting ocular symptoms include painless blurred vision or severe visual loss, floaters, and scotomata.

Examination reveals perivascular exudation or cuffing that predominantly involves the arteries, the veins, or both; varying degrees of anterior chamber cell and flare; and vitritis. These findings may be accompanied by retinal hemorrhages, cotton-wool spots, exudates, cystoid macular edema (CME), neovascularization, vitreous hemorrhage, or disc edema.

The history and clinical examination are by far the most powerful diagnostic tools in evaluating this complex group of diseases. After a thorough review of systems and physical examination, the lack of findings indicating a systemic disease makes the pretest probability of disease very low and, thus, reduces the predicative value of any diagnostic tests.

Some investigators have shown that patients with retinal vasculitis presenting with symptoms and signs confined to the eye needlessly undergo exhaustive and expensive diagnostic evaluation. When George et al reviewed a series of patients with primary retinal vasculitis, they found that 96% of them had a negative review of systems; however, all patients underwent an exhaustive battery of tests.[12] A diagnosis was established in only 1 patient; false-positive results were obtained in 21% of patients. The shotgun approach has no place in evaluating a patient with retinal vasculitis. It invariably results in false-positive results, which, in turn, leads to more unnecessary testing, cost, and inconvenience to the patient.

Fluorescein angiography is an important aspect of the evaluation process. Findings may include staining of the vessel walls, beaded vessels, microaneurysms, telangiectatic vessels, capillary nonperfusion, neovascularization, and CME. Fluorescein angiography helps to classify the vasculitic process as either occlusive or nonocclusive. Perhaps more importantly, fluorescein angiography aids in making the determination as to whether a noninflammatory retinal vascular disease is present.

Numerous tests are ordered for all patients with intraocular inflammation, primarily to rule out masquerade syndromes and to evaluate the status of the patient's health. Such a limited workup includes CBC count, urinalysis, FTA-ABS, ACE, and chest radiography. Tests for syphilis and sarcoidosis help to rule in or rule out these 2 readily treatable diseases, which can present as any type of intraocular inflammation. From here, aspects of the history and clinical examination are used to formulate a differential diagnosis. If the pretest probability of disease is sufficiently high (but not too high), then further testing should be performed accordingly or treatment initiated if a clinical diagnosis is established.

A flowchart summarizing the diagnostic approach to retinal vasculitis is provided in the image below.

Flowchart for the evaluation of retinal vasculitisFlowchart for the evaluation of retinal vasculitis.

This chart is intended to serve as a guide for the thought process involved in approaching the diagnosis of retinal vasculitis. Implicit in this diagnostic approach is the need for consultation with an internist and possibly a rheumatologist or an infectious disease specialist. Most cases are idiopathic (sometimes called Eales disease), and many of the systemic diseases are clinical diagnoses (eg, Behçet disease, SLE). In these cases, laboratory tests are supportive but not diagnostic.

Inflammatory chorioretinopathies

This diverse group of choroidal inflammatory disorders is named because of their association with multiple, well-circumscribed, whitish yellow lesions affecting the choroid and choriocapillaris-retinal pigment epithelium (RPE) complex. Certain well-defined ocular inflammatory and infectious conditions, such as sarcoidosis, VKH disease, sympathetic ophthalmia, mycobacterium avium complex, and P carinii choroiditis, can be associated with well-circumscribed choroidal lesions. These clinical entities nearly always are associated with other ocular and extraocular manifestations, thereby posing little diagnostic dilemma. However, intraocular large cell lymphoma commonly presents with multiple punctate subretinal infiltrates that can be confused easily with an inflammatory process.

This discussion is limited to those disorders that are idiopathic and inflammatory in nature. The term white dot syndromes is intentionally vague because of the lack of understanding of their pathogenesis. Consequently, most of the diseases have descriptive terms attached to them, such as evanescent and placoid, implying ignorance as to their etiology. Some of these entities have overlapping clinical findings, prompting a debate as to whether they represent parts of a spectrum of a single disease or whether they are distinct clinical disorders.

These diseases are all clinical diagnoses; therefore, the clinical presentation and, to a larger degree, the ocular findings are vital in the diagnostic evaluation. Several of these diseases have an acute onset (eg, multiple evanescent white dot syndrome [MEWDS], acute posterior multifocal placoid pigment epitheliopathy [APMPPE]), whereas others are insidious in onset (eg, birdshot retinochoroiditis). Most of these diseases have little, if any, anterior or vitreous cellular activity, except birdshot retinochoroiditis, which can be associated with significant vitritis (without snowbanking), retinal vasculitis, and CME. A fundus finding, such as a granular appearance of the macula, is pathognomonic for MEWDS, whereas the lesions of other diseases occasionally can be confused with each other. The authors have found fluorescein angiography to be a helpful test in evaluating these patients.

Table 3 outlines clinical features and tests that are useful in the diagnostic approach to white dot syndromes.

Laboratory investigation of these patients is uniformly unproductive with the exception of birdshot retinochoroiditis. The association between this disease and the HLA-A29 phenotype is very strong. Testing for the HLA-A29 antigen is both sensitive and specific and has a relative risk of 132 to 157. Patients with a moderately high pretest probability of disease benefit from HLA typing because the result may rule in or rule out disease.

Table 3. Clinical Features and Tests Useful in Diagnostic Approach to White Dot Syndromes (Open Table in a new window)

Clinical PresentationCellular ActivityFundus LesionsFluorescein AngiographyOther Tests
Birdshot retinochoroiditisInsidious onset, middle age, F>M, bilateral (90%)Mild anterior chamber cells, mild-to-moderate vitritis100-300 µm, cream colored, indistinct, posterior pole to equatorEarly hyperfluorescence, macular and disc leakageHLA-A29+ (90%), electroretinography (ERG) findings abnormal
APMPPEAcute onset, ± viral prodrome, young, M=F, bilateral, ± CNS symptoms1+ anterior chamber cells, ± mild vitreous cellsLarge, flat, cream colored, placoid, primarily in posterior poleEarly hypofluorescence with late stainingCerebrospinal fluid (CSF) pleocytosis, ERG and electroretinography (EOG) findings negative
MEWDSAcute onset, young, F>M, unilateral (90%), ± viral prodrome± mild vitreous cellsMany, discrete, white, 100-200 µm, posterior pole, granular maculaWreath pattern of hyperfluorescence with late stainingERG and EOG findings very abnormal
Serpiginous choroidopathyInsidious onset, middle age, M=F, bilateral± Mild anterior chamber and vitreous cellsLarge geographic, starts peripapillary with helicoid progressionWindow defects, loss of choriocapillaris, acute lesion shows blocked fluorescence...
Punctate inner choroidopathy (PIC)Insidious onset, young, myopic, F>M, bilateralQuiet100-300 µm, white, punctate, posterior poleBlock early, stain lateERG and EOG findings normal
Multifocal choroiditis with panuveitis (MCP)Insidious onset, young, myopic, F>M, bilateral (80%)± Mild anterior chamber cells, vitreous cells (100%)100-300 µm, multifocal, punched-outEarly hyperfluorescence, late stainingERG and EOG findings normal
Acute retinal pigment epitheliitis (ARPE)Acute onset, young, M=F, unilateral (75%)QuietSmall black spots with halo around foveaEarly blockage with halo of hyperfluorescence and late stainingEOG findings negative
Previous
Next

Surgical Management of Patient With Uveitis

Background

Surgical indications in the management of uveitis include visual rehabilitation, diagnostic biopsy when findings may change the treatment plan, and removal of media opacities to monitor the posterior segment. Despite advances in anti-inflammatory and immunomodulatory therapy, permanent structural changes can occur in the eye that are best managed with surgery (eg, cataract formation, secondary glaucoma due to pupillary block or angle closure, retinal detachment).

In preparing the eye for surgery, medical treatment should be intensified for a minimum of 3 months to achieve complete quiescence of inflammation (ie, complete eradication of anterior chamber cells, active vitreous cells). Generally, beginning 24-48 hours preoperatively, topical prednisolone acetate 1% is administered every 1-2 hours (while awake) with prednisone (1 mg/kg) depending on the nature of the inflammation. Intraocular and/or periocular steroids may be administered intraoperatively. Systemic and topical medications are tapered slowly postoperatively depending on the degree of inflammation.

Table 4. Specific Surgical Conditions Possibly Encountered by Practitioner of Uveitis (Open Table in a new window)

ConditionCommon EtiologiesSurgical ProcedureComment
Corneal opacificationHerpetic keratitis, peripheral ulcerative keratitisPenetrating keratoplastyHigh risk of rejection or recurrence
Band keratopathyJuvenile idiopathic arthritis (JIA)Chelation, excimer laserMay require general anesthesia
CataractAny type of uveitisPhacoemulsification ± intraocular lens (IOL), vitrectomy and lensectomySee below (Cataract surgery in patient with uveitis)
IOL precipitatesChronic anterior uveitisYAG laser "polishing"May be recurrent and require long-term topical steroid use
Pupillary membranesJIAYAG laser, pars plana vitrectomy (PPV)High YAG laser energy may exacerbate uveitis
Glaucoma, pupillary block, 2° angle closureChronic anterior uveitis, herpetic uveitis, Fuchs heterochromic iridocyclitisLaser iridectomy, filtering surgery with mitomycin vs aqueous drainage tubeConsider performing laser peripheral iridectomy when 270° or more of posterior synechiae
Vitreous opacificationIntermediate uveitis, sarcoidosis, vitreous hemorrhage, intraocular lymphomaPPVSee indications for vitrectomy in patient with uveitis.
Epiretinal membraneIntermediate uveitis, any posterior uveitisPPV/membrane peelingSee indications for vitrectomy in patient with uveitis.
Retinal detachmentIntermediate uveitis, cytomegalovirus (CMV) retinitis, acute retinal necrosis (ARN)PPV ± scleral buckle, long-acting gas, or silicone oilSee indications for vitrectomy in patient with uveitis.
Chronic CMEAny type of uveitisPPV (possibly), intravitreal triamcinolone and/or bevacizumabQuality of evidence is weak
Choroidal neovascular membraneMultifocal choroiditis, punctate inner choroiditis, ocular histoplasmosis syndromeThermal laser (extrafoveal), photodynamic therapy (ocular histoplasmosis syndrome [OHS]), intravitreal bevacizumab, submacular surgery Trial of aggressive anti-inflammatory or immunosuppressive therapy first if possible
Retinal/optic disc neovascularizationSarcoidosis, intermediate uveitis, Behçet diseasePhotocoagulation, cryopexy, intravitreal bevacizumabMay respond to corticosteroids
Progressive unresponsive chorioretinal lesions of unknown etiologyNeoplastic and infectious diseasesChorioretinal biopsyReferral to institutions familiar with procedure and expertise in interpretation of specimen
Medically unresponsive intermediate uveitisPars planitis, sarcoidosisPars plana cryopexy or laser photocoagulation



PPV



Double freeze thaw to area of pars plana exudate

Indications for vitrectomy in patient with uveitis

Posterior and intermediate uveitis may be associated with significant vitreous opacification that is unresponsive to medical therapy. Visually disabling opacities may occur with intermediate uveitis. Retinal or optic disc neovascularization may complicate conditions associated with vasculitis or vascular occlusion (eg, pars planitis, Behçet disease, sarcoidosis), resulting in vitreous hemorrhage. Modern vitrectomy offers a therapeutic option in these situations.

Mediators of intraocular inflammation stimulate fibrous tissue proliferation, thus predisposing the eye to epiretinal membrane formation. No prospective clinical trials in the literature exist comparing outcomes of membrane peeling in eyes with uveitis and those with idiopathic causes. However, Dev et al reported favorable visual results in a group of patients with pars planitis.[21] The investigators also noted a postoperative improvement in the level of vitritis in all patients. Because the macula may already have irreversible damage (eg, scaring, chronic cystoid macular edema [CME], macular hole, capillary nonperfusion), proper patient selection and realistic patient expectations are important.

Conditions resulting in large areas of thin and atrophic retina (eg, CMV retinitis, ARN) commonly are complicated by retinal detachment. These types of retinal detachments usually are associated with atrophic posterior breaks. Vitrectomy with long-acting gas or silicone tamponade commonly is used with or without scleral buckling. Scleral buckling alone usually is not successful.

At times, potentially life-threatening malignant processes or infectious uveitis may be mistaken for immune-mediated intraocular inflammation. A thorough review of systems and knowledge of response to prior therapy are critical. Vitrectomy or needle aspiration for diagnostic and therapeutic reasons is indicated whenever the intraocular inflammation responds poorly or incompletely to appropriate therapy or if clinical suspicion is raised for intraocular neoplasia or infection. Common masquerade syndromes in patients with vitritis include intraocular large cell lymphoma, chronic fungal or anaerobic endophthalmitis, and retinal detachment. Whenever the diagnosis of lymphoma is entertained, the threshold to perform vitrectomy should be low; it is better to have a high number of negative biopsy results rather than to miss the diagnosis of this lethal condition. Proper specimen retrieval and handling and communication with the cytopathologist or microbiology laboratory are critical.

Several reports are available in the ophthalmic literature (all of them are retrospective and uncontrolled) that address the issue of therapeutic vitrectomy as a means of moderating intraocular inflammation. Vitrectomy may debulk the antigenic stimulus in the eye, thus reducing intraocular inflammation and CME, and allow tapering or elimination of systemic therapy. While the theoretical advantages of vitrectomy in chronic uveitis seem apparent, and although the body of evidence is growing, the quality of the evidence is weak. The role of vitrectomy in the management of uveitis will likely expand to include the placement of intraocular sustained-release drug delivery devices as well as to modulate the inflammatory response. Likewise, as polymerase chain reaction (PCR) becomes more widely used, diagnostic vitrectomy will be performed more regularly to confirm or establish a diagnosis and to guide therapy.

Cataract surgery in patient with uveitis

Cataracts occur in most patients with chronic or recurrent uveitis likely due to inflammatory mediators and corticosteroid-induced mechanisms. Indications for cataract surgery include the following: (1) visually significant lens opacity with good visual potential, (2) in combination with vitreoretinal surgery to better visualize the posterior segment, (3) lens-induced uveitis, and (4) impairment of fundus assessment. Prognosis is strongly dependent on preoperative control of all intraocular inflammation for a minimum of 3 months but preferably 3-6 months. Use aggressive topical, periocular, and oral steroid regimens in combination with immunomodulatory therapy if needed. Bringing the eye into a state of quiescence is key to a favorable outcome.

Modern techniques have improved surgical outcomes. Evidence suggests that phacoemulsification in conjunction with small incision surgery causes less breakdown of the blood-aqueous barrier compared with extracapsular techniques. Similarly, other investigators have found that clear corneal incisions are less likely to cause early postoperative inflammation than sclerocorneal tunnels. The optimal lens biomaterial has yet to be found, but some evidence exists in the literature that heparin-modified IOLs may provoke less inflammation than other materials. Until a superior biomaterial is discovered, placement of an all polymethyl methacrylate (PMMA) lens in the capsular bag with attention to meticulous cortical cleanup is recommended.

Cataract extraction and IOL placement is probably safe in patients with Fuchs heterochromic iridocyclitis, pars planitis, acute posterior multifocal placoid pigment epitheliopathy (APMPPE), ocular histoplasmosis, and chronic well-controlled anterior uveitis. Consider vitrectomy/lensectomy in patients with JIA, panuveitis, and granulomatous diseases. Placement of an IOL in children with JIA probably should be avoided, although some reports offer encouraging results with IOL implantation in this otherwise complicated form of uveitis.

Previous
 
Contributor Information and Disclosures
Author

Robert H Janigian Jr, MD  Clinical Assistant Professor, Department of Surgery (Ophthalmology), Brown University Medical School

Robert H Janigian Jr, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, and Rhode Island Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

John D Sheppard Jr, MD, MMSc  Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

R Christopher Walton, MD  Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, University of Tennessee College of Medicine

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Healthcare Executives, American Uveitis Society, Association for Research in Vision and Ophthalmology, and Retina Society

Disclosure: Nothing to disclose.

Ralph Garzia, OD  Assistant Dean for Clinical and Academic Programs, Associate Professor, College of Optometry, University of Missouri at St Louis

Ralph Garzia, OD is a member of the following medical societies: American Academy of Optometry and American Optometric Association

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous coauthor, David Young, MD, to the development and writing of this article.

References
  1. Opremcek EM. Uveitis. In: A Clinical Manual for Ocular Inflammation. New York: Springer-Verlag; 1995.

  2. Smith RE, Nozik RA. Uveitis. In: A Clinical Approach to Diagnosis and Management. 3rd ed. Lippincott Williams & Wilkins; 2003.

  3. Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol. Sep 1990;108(9):1291-3. [Medline].

  4. Sackett DL, Richardson WS, Rosenberg W, Haynes B. Evidence-based medicine. In: How to Practice and Teach EBM. ed. Harcourt Health Sciences; 1996.

  5. Sandler G. The importance of the history in the medical clinic and the cost of unnecessary tests. Am Heart J. Dec 1980;100(6 Pt 1):928-31. [Medline].

  6. [Guideline] Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. Sep 2005;140(3):509-16. [Medline].

  7. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D'Amico DJ, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. May 1996;114(5):593-9. [Medline].

  8. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. Mar 2004;111(3):491-500; discussion 500. [Medline].

  9. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol. Jan 1996;121(1):35-46. [Medline].

  10. Wang TJ, Hu CC, Lin HC. Increased risk of anterior uveitis following herpes zoster: a nationwide population-based study. Arch Ophthalmol. Apr 2012;130(4):451-5. [Medline].

  11. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol. Feb 15 1987;103(2):131-6. [Medline].

  12. George RK, Walton RC, Whitcup SM, Nussenblatt RB. Primary retinal vasculitis. Systemic associations and diagnostic evaluation. Ophthalmology. Mar 1996;103(3):384-9. [Medline].

  13. [Guideline] Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. Oct 2000;130(4):492-513. [Medline].

  14. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. Oct 2011;118(10):1916-1926. [Medline].

  15. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. May 2009;68(5):696-701. [Medline].

  16. Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. Jul 2008;8(4):339-47. [Medline].

  17. Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). Oct 2008;47(10):1510-4. [Medline].

  18. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. Jan 2008;28(1):41-5. [Medline].

  19. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. Sep 2008;126(9):1191-201. [Medline].

  20. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. Arch Ophthalmol. May 2011;129(5):545-553. [Medline].

  21. Dev S, Mieler WF, Pulido JS, Mittra RA. Visual outcomes after pars plana vitrectomy for epiretinal membranes associated with pars planitis. Ophthalmology. Jun 1999;106(6):1086-90. [Medline].

  22. American Academy of Ophthalmology. Section 9. Intraocular inflammation and uveitis. In: Basic and Clinical Science Course. San Francisco, Calif: American Academy of Ophthalmology; 2007-2008.

  23. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. Dec 2005;140(6):1096-105. [Medline].

  24. Canadian Medical Association Journal. How to read clinical journals: II. To learn about a diagnostic test. Can Med Assoc J. Mar 15 1981;124(6):703-10. [Medline].

  25. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. Jul-Aug 2005;50(4):364-88. [Medline].

  26. Chang TS, Aylward GW, Davis JL, et al. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Ophthalmology. Jul 1995;102(7):1089-97. [Medline].

  27. Fagan TJ. Letter: Nomogram for Bayes theorem. N Engl J Med. Jul 31 1975;293(5):257. [Medline].

  28. Foster CS, Rashid S. Management of coincident cataract and uveitis. Curr Opin Ophthalmol. Feb 2003;14(1):1-6. [Medline].

  29. Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. Philadelphia: WB Saunders; 2002.

  30. Gunduz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus. 2006;21(5):E9. [Medline].

  31. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. Feb 2 1994;271(5):389-91. [Medline].

  32. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. Mar 2 1994;271(9):703-7. [Medline].

  33. Kanski JJ, Shun-Shin GA. Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology. Oct 1984;91(10):1247-52. [Medline].

  34. Kerkhoff FT, Lamberts QJ, van den Biesen PR. Rhegmatogenous retinal detachment and uveitis. Ophthalmology. Feb 2003;110(2):427-31. [Medline].

  35. LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. Jan 15 1992;113(1):33-5. [Medline].

  36. Lobo A, Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. Ophthalmology. Mar 2003;110(3):595-9. [Medline].

  37. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis. In: Fundamentals and Clinical Practice. 3rd ed. Mosby-Year Book; 2004.

  38. Quillen DA, Davis JB, Gottlieb JL, et al. The white dot syndromes. Am J Ophthalmol. Mar 2004;137(3):538-50. [Medline].

  39. Rosenbaum JT, Holland GN. Uveitis and the Tower of l. Arch Ophthalmol. May 1996;114(5):604-5. [Medline].

  40. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol. Mar 1992;76(3):137-41. [Medline].

  41. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology. In: A Basic Science for Clinical Medicine. 2nd ed. Lippincott-Raven Publishers; 1991.

Previous
Next
 
Flowchart for the evaluation of retinal vasculitis.
Table 1. Various Clinical Scenarios Encountered by Practitioner of Uveitis
Type of InflammationAssociated FactorsSuspected DiseaseLaboratory Tests
Acute/sudden onset, severe with or without fibrin membrane or hypopyonArthritis, back pain, GI/genitourinary symptomsSeronegative spondyloarthropathiesHLA-B27, sacroiliac films
Aphthous ulcersBehçet diseaseHLA-B5, HLA-B51
Postsurgical, posttraumaticInfectious endophthalmitisVitreous tap, vitrectomy
Medication inducedRifabutinNone
NoneIdiopathicPossibly HLA-B27
Moderate severity of pain and rednessShortness of breath, African descent, subcutaneous nodulesSarcoidosisSerum ACE, lysozyme, chest radiograph or chest CT scan, gallium scan, biopsy
PosttraumaticTraumatic iritis...
Increased IOP, sectorial iris atrophy, corneal dendriteHerpetic iritis...
Poor response to steroid, manifestations of 2° or 3° syphilis, HIVSyphilisRapid plasma reagent (RPR) or VDRL, FTA-ABS
Postcataract extraction, white plaque on posterior capsuleEndophthalmitis, intraocular lens (IOL)- related iritisVitrectomy and/or culture, consider anaerobic and fungal cultures
Medication inducedEtidronate (Didronel), metipranolol (OptiPranolol), latanoprost (Xalatan)
History of HIV, alcohol abuse, exposure to infected individuals, residence in endemic regionsTuberculosisPurified protein derivative (PPD), chest radiograph, referral to infectious disease specialist
NoneIdiopathic...
Chronic, minimal signs of redness or painChild, especially with arthritisJIA-related iridocyclitisAntinuclear antibody (ANA), erythrocyte sedimentation rate (ESR)
Heterochromia, diffuse stellate keratic precipitate, unilateralFuchs uveitis syndromeNone
PostsurgicalLow-grade endophthalmitis, IOLVitrectomy, capsulectomy with culture
NoneIdiopathicLyme titers (possibly)
Table 2. Other Entities Reported to Cause or Confused With Intermediate Uveitis
Clinical EntityDiagnostic Tests
Idiopathic (pars planitis)None
SarcoidosisACE, chest radiography, gallium scan, biopsy (possibly)
Multiple sclerosisMRI and neurologic consultation if history of neurologic symptoms or optic neuritis, HLA-DR2
Lyme diseaseLyme serology (immunoglobulin [Ig]G/IgM Western immunoblot testing) if from endemic area and/or presence of systemic signs
SyphilisVDRL, FTA-ABS
Inflammatory bowel diseaseGI consultation
Whipple diseaseGI consultation
LymphomaVitreous cytology with immunophenotyping, lumbar puncture for cytology, neuroimaging
Table 3. Clinical Features and Tests Useful in Diagnostic Approach to White Dot Syndromes
Clinical PresentationCellular ActivityFundus LesionsFluorescein AngiographyOther Tests
Birdshot retinochoroiditisInsidious onset, middle age, F>M, bilateral (90%)Mild anterior chamber cells, mild-to-moderate vitritis100-300 µm, cream colored, indistinct, posterior pole to equatorEarly hyperfluorescence, macular and disc leakageHLA-A29+ (90%), electroretinography (ERG) findings abnormal
APMPPEAcute onset, ± viral prodrome, young, M=F, bilateral, ± CNS symptoms1+ anterior chamber cells, ± mild vitreous cellsLarge, flat, cream colored, placoid, primarily in posterior poleEarly hypofluorescence with late stainingCerebrospinal fluid (CSF) pleocytosis, ERG and electroretinography (EOG) findings negative
MEWDSAcute onset, young, F>M, unilateral (90%), ± viral prodrome± mild vitreous cellsMany, discrete, white, 100-200 µm, posterior pole, granular maculaWreath pattern of hyperfluorescence with late stainingERG and EOG findings very abnormal
Serpiginous choroidopathyInsidious onset, middle age, M=F, bilateral± Mild anterior chamber and vitreous cellsLarge geographic, starts peripapillary with helicoid progressionWindow defects, loss of choriocapillaris, acute lesion shows blocked fluorescence...
Punctate inner choroidopathy (PIC)Insidious onset, young, myopic, F>M, bilateralQuiet100-300 µm, white, punctate, posterior poleBlock early, stain lateERG and EOG findings normal
Multifocal choroiditis with panuveitis (MCP)Insidious onset, young, myopic, F>M, bilateral (80%)± Mild anterior chamber cells, vitreous cells (100%)100-300 µm, multifocal, punched-outEarly hyperfluorescence, late stainingERG and EOG findings normal
Acute retinal pigment epitheliitis (ARPE)Acute onset, young, M=F, unilateral (75%)QuietSmall black spots with halo around foveaEarly blockage with halo of hyperfluorescence and late stainingEOG findings negative
Table 4. Specific Surgical Conditions Possibly Encountered by Practitioner of Uveitis
ConditionCommon EtiologiesSurgical ProcedureComment
Corneal opacificationHerpetic keratitis, peripheral ulcerative keratitisPenetrating keratoplastyHigh risk of rejection or recurrence
Band keratopathyJuvenile idiopathic arthritis (JIA)Chelation, excimer laserMay require general anesthesia
CataractAny type of uveitisPhacoemulsification ± intraocular lens (IOL), vitrectomy and lensectomySee below (Cataract surgery in patient with uveitis)
IOL precipitatesChronic anterior uveitisYAG laser "polishing"May be recurrent and require long-term topical steroid use
Pupillary membranesJIAYAG laser, pars plana vitrectomy (PPV)High YAG laser energy may exacerbate uveitis
Glaucoma, pupillary block, 2° angle closureChronic anterior uveitis, herpetic uveitis, Fuchs heterochromic iridocyclitisLaser iridectomy, filtering surgery with mitomycin vs aqueous drainage tubeConsider performing laser peripheral iridectomy when 270° or more of posterior synechiae
Vitreous opacificationIntermediate uveitis, sarcoidosis, vitreous hemorrhage, intraocular lymphomaPPVSee indications for vitrectomy in patient with uveitis.
Epiretinal membraneIntermediate uveitis, any posterior uveitisPPV/membrane peelingSee indications for vitrectomy in patient with uveitis.
Retinal detachmentIntermediate uveitis, cytomegalovirus (CMV) retinitis, acute retinal necrosis (ARN)PPV ± scleral buckle, long-acting gas, or silicone oilSee indications for vitrectomy in patient with uveitis.
Chronic CMEAny type of uveitisPPV (possibly), intravitreal triamcinolone and/or bevacizumabQuality of evidence is weak
Choroidal neovascular membraneMultifocal choroiditis, punctate inner choroiditis, ocular histoplasmosis syndromeThermal laser (extrafoveal), photodynamic therapy (ocular histoplasmosis syndrome [OHS]), intravitreal bevacizumab, submacular surgery Trial of aggressive anti-inflammatory or immunosuppressive therapy first if possible
Retinal/optic disc neovascularizationSarcoidosis, intermediate uveitis, Behçet diseasePhotocoagulation, cryopexy, intravitreal bevacizumabMay respond to corticosteroids
Progressive unresponsive chorioretinal lesions of unknown etiologyNeoplastic and infectious diseasesChorioretinal biopsyReferral to institutions familiar with procedure and expertise in interpretation of specimen
Medically unresponsive intermediate uveitisPars planitis, sarcoidosisPars plana cryopexy or laser photocoagulation



PPV



Double freeze thaw to area of pars plana exudate
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.